Cite
HARVARD Citation
Hjardem, E. et al. (2007). Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Annals of the rheumatic diseases. 66 (9), pp. 1184-1189. [Online].